Changchun BCHT Biotechnology Co.

Shanghai Stock Exchange 688276.SS

Changchun BCHT Biotechnology Co. Return on Assets (ROA) for the year ending December 31, 2023: 9.93%

Changchun BCHT Biotechnology Co. Return on Assets (ROA) is 9.93% for the year ending December 31, 2023, a 134.27% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Changchun BCHT Biotechnology Co. Return on Assets (ROA) for the year ending December 31, 2022 was 4.24%, a -27.36% change year over year.
Changchun BCHT Biotechnology Co. Return on Assets (ROA) for the year ending December 31, 2021 was 5.83%, a -65.58% change year over year.
Changchun BCHT Biotechnology Co. Return on Assets (ROA) for the year ending December 31, 2020 was 16.95%, a 21.42% change year over year.
Changchun BCHT Biotechnology Co. Return on Assets (ROA) for the year ending December 31, 2019 was 13.96%, a 53.73% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Shanghai Stock Exchange: 688276.SS

Changchun BCHT Biotechnology Co.

CEO	Mr. Wei Kong
IPO Date	June 25, 2021
Location	China
Headquarters	1260 Huoju Road
Employees	1,241
Sector	Healthcare
Industries Vaccines Biotechnology Pharmaceuticals

Description

Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally. Its products include live herpes zoster vaccine; live varicella vaccine; live, nasal, and freeze-dried influenza vaccine; and Rabies vaccine (vero cell) for humans. The company was founded in 2004 and is based in Changchun, China.

Key trends

Past 5 years